**WHAT IS CLAIMED:**

1. An antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising:

(a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 19, or a variant thereof in which one or two amino acids have been changed;

(b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 20, or a variant thereof in which one or two amino acids have been changed;

(c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 21, or a variant thereof in which one or two amino acids have been changed;

(d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 22, or a variant thereof in which one or two amino acids have been changed;

(e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 23, or a variant thereof in which one or two amino acids have been changed; and

(f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 24, or a variant thereof in which one or two amino acids have been changed,

wherein the antibody binds to TGFβ1 and to TGFβ2 with greater affinity than to TGFβ3.

2. The antibody of claim 1, that comprises an amino acid sequence at least 95% identical to a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 6.

3. The antibody of claim 1 or 2, in which one or more heavy chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.

4. The antibody of claim 1, comprising an amino acid sequence at least 95% identical to a light chain variable region amino acid sequence set forth in SEQ ID NO: 8.

5. The antibody of claim 4, comprising a light chain variable region amino acid sequence set forth in SEQ ID NO: 8.

6. An antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising a light chain variable region and a heavy chain variable region, wherein

(a) the light chain variable region comprises at least a CDR1 amino acid sequence set out in SEQ ID NO: 22, a CDR2 amino acid sequence set out in SEQ ID NO: 23, and a CDR3 amino acid sequence set out in SEQ ID NO: 24; and wherein

(b) the heavy chain variable region comprises at least a CDR1 amino acid sequence set out in SEQ ID NO: 19, a CDR2 amino acid sequence set out in SEQ ID NO: 20, and a CDR3 amino acid sequence set out in SEQ ID NO: 21.

7. The antibody of any one of claims 1 to 6, further comprising a heavy chain constant region, wherein the heavy chain constant region is a modified or unmodified IgG, IgM, IgA, IgD, IgE, a fragment thereof, or combinations thereof.

8. The antibody of any one of claims 4 to 7, in which one or more light chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.

9. The antibody of any one of claims 1 or 6, wherein the antibody is selected from XPA.42.089 having a heavy chain variable region amino acid sequence set out in SEQ ID NO: 6 and a light chain variable region amino acid sequence set out in SEQ ID NO: 8.

10. The antibody of any of claims 4 to 9, further comprising a human light chain constant region attached to said light chain variable region.

11. The antibody of claim 10, wherein the light chain constant region is a modified or unmodified lambda light chain constant region, a kappa light chain constant region, a fragment thereof, or combinations thereof.

12. An antibody of any one of the preceding claims that binds TGFβ1 and TGFβ2 with an affinity Kd of $10^{-6}$ M or less.

13. An antibody of any one of claims 1 to 12, wherein the antibody neutralizes activity of TGFβ1 and TGFβ2 to a greater extent than TGFβ3.

14. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the heavy chain or light chain of any one of claims 1 to 13.

15. An expression vector comprising the nucleic acid molecule of claim 14 operably linked to an expression control sequence.

16. A host cell comprising the vector of claim 15 or a nucleic acid molecule of claim 14.

17. The host cell of claim 16, comprising a nucleic acid molecule encoding a heavy chain and a light chain variable region, wherein the heavy chain and light chain nucleic acids are expressed by different nucleic acids or on the same nucleic acid.

18. A method of using the host cell of claim 16 or 17 to produce an antibody, comprising culturing the host cell of claim 16 or 17 under suitable conditions and recovering said antibody.

19. An antibody produced by the method of claim 18.

20. A sterile pharmaceutical composition comprising the antibody of any one of claims 1-13 and 19 and a pharmaceutically acceptable carrier.

21. Use of an antibody of any one of claims 1 to 13 or a pharmaceutical composition of claim 20 for the manufacture of a medicament for treating a disease, condition or disorder associated with TGFβ expression in a subject in need thereof.

22. The use of claim 21, wherein the disease, condition or disorder is selected from the group consisting of cancer, eye diseases, conditions or disorders, ophthalmic fibroses or fibrosis of the eye, pulmonary fibrosis, idiopathic pulmonary fibrosis, peribronchiolar fibrosis, interstitial lung disease, chronic obstructive pulmonary disease (COPD), small airway disease (e.g., obstructive bronchiolitis), emphysema, adult or acute respiratory distress syndrome (ARDS), acute lung injury (ALI); pulmonary fibrosis due to infectious or toxic agents; kidney fibrosis, glomerulonephritis (GN) of all etiologies, mesangial proliferative GN, immune GN, and crescentic GN, glomerulosclerosis, tubulointerstitial injury, renal interstitial fibrosis, renal fibrosis and all causes of renal interstitial fibrosis, renal fibrosis resulting from complications of drug exposure, cyclosporin treatment of transplant recipients, HIV-associated nephropathy, transplant necropathy, diabetic kidney disease (diabetic nephropathy), nephrogenic systemic fibrosis, diabetes, idiopathic retroperitoneal fibrosis, scleroderma, liver fibrosis, hepatic diseases associated with excessive scarring and progressive sclerosis, liver cirrhosis, disorders of the biliary tree, hepatic dysfunction attributable to infections, fibrocystic diseases, cardiovascular diseases, congestive heart failure, dilated cardiomyopathy; myocarditis; vascular stenosis cardiac fibrosis (post-infarction cardiac fibrosis), post myocardial infarction, left ventricular hypertrophy, veno-occlusive disease, restenosis, post-angioplasty restenosis, arteriovenous graft failure, atherosclerosis, hypertension, hypertensive heart disease, cardiac hypertrophy, hypertrophic cardiomyopathy, heart failure, disease of the aorta, progressive systemic sclerosis, polymyositis, systemic lupus erythematosus, dermatomyositis, fascists, Raynaud's syndrome, rheumatoid arthritis, , Peyronie's disease, systemic sclerosis, post-spinal cord injury, osteoporosis, Camurati-Engelmann disease, Crohn's disease, scarring, Marfan syndrome,

premature ovarian failure, Alzheimer's Disease and Parkinson's Disease, fibrosis due to surgical incisions or mechanical trauma, fibrosis associated with ocular surgery; and excessive or hypertrophic scar or keloid formation in the dermis occurring during wound healing resulting from trauma or surgical wounds.

23. The use of claim 22, wherein the disease, condition or disorder is an eye disease, condition or disorder selected from the group consisting of fibroproliferative disorders, fibrosis of the eye, ophthalmic fibroses, retinal dysfunction, fibrosis associated with retinal dysfunction, wet or dry macular degeneration, proliferative vitreoretinopathy, vitreoretinopathy of any etiology, fibrosis associated with ocular surgery such as treatment of glaucoma, retinal reattachment, cataract extraction, or drainage procedures of any kind, scarring in the cornea and conjunctiva, fibrosis in the corneal endothelium, alkali burn (e.g., alkali burn to the cornea), post-cataract surgery fibrosis of the lens capsule, excess scarring in the tissue around the extraocular muscles in the strabismus surgery, anterior subcapsular cataract and posterior capsule opacification, anterior segment fibrotic diseases of the eye, fibrosis of the corneal stroma (e.g., associated with corneal opacification), fibrosis of the trabecular network (e.g., associated with glaucoma), posterior segment fibrotic diseases of the eye, fibrovascular scarring (e.g., in retinal or choroidal vasculature of the eye), retinal fibrosis, epiretinal fibrosis, retinal gliosis, subretinal fibrosis (e.g., associated with age related macular degeneration), fibrosis associated with post-retinal and glaucoma surgery, and tractional retinal detachment in association with contraction of the tissue in diabetic retinopathy.

24. The use of claim 22, wherein the disease, condition or disorder is a fibroproliferative eye disease, condition, or disorder, fibrosis of the eye, or ophthalmic fibrosis.

25. Use of an antibody of any one of claims 1 to 13 or a pharmaceutical composition of claim 20 for the manufacture of a medicament for treating cancer in a subject in need thereof.

26. The use of claim 25, wherein the antibody or composition increases the number of natural killer (NK) cells in a tumor and/or improves NK cell cytolytic activity.

27. The use of any one of claims 25 to 26, wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma.

28. Use of an antibody of any one of claims 1 to 13 or a pharmaceutical composition of claim 20 for the manufacture of a medicament for treating fibrosis in a subject in need thereof.

29. A composition comprising an antibody of any one of claims 1 to 13 or a pharmaceutical composition of claim 20 for use in treating a condition or disorder associated with TGFβ expression.